Related Experiment Video
Updated: Jul 18, 2026

08:49
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based
1Department of Biochemistry, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland. pkolb@bioc.unizh.ch
Journal of Medicinal Chemistry
|December 8, 2006
Summary
The Decomposition and Identification of Molecules (DAIM) program efficiently breaks down chemical compounds for fragment-based drug discovery. DAIM
Area of Science:
- Computational Chemistry
- Cheminformatics
- Drug Discovery
Background:
- Fragment-based drug discovery (FBDD) relies on analyzing and utilizing molecular fragments.
- Efficient computational tools are needed to process large chemical libraries for FBDD.
Purpose of the Study:
- To evaluate the DAIM (Decomposition and Identification of Molecules) program for fragment selection in docking and library analysis.
- To assess DAIM's effectiveness in identifying key molecular fragments for drug design.
Main Methods:
- DAIM was used to decompose 130 ligands from known protein-ligand complexes.
- A fingerprint-based identification technique was employed to select anchor fragments for docking.
- DAIM was applied to analyze a library of 1.85 million commercially available compounds.
Main Results:
- DAIM-selected fragments yielded superior docking results compared to size-based or random selection.
- The most frequent fragments identified by DAIM in a large library significantly overlapped with fragments found in known drugs.
- DAIM facilitated successful in silico screening for beta-secretase and EphB4 kinase inhibitors.
Conclusions:
- DAIM is a valuable tool for fragment-based docking and large-scale database analysis in drug discovery.
- The program effectively identifies relevant fragments for drug design and screening.
- DAIM shows promise for future applications in de novo ligand design.

